Nanotechnology applications in cancer.

By Shuming Nie, Yun Xing, Gloria J. Kim, J. Simons. Annual Review of Biomedical Engineering, 2007

1,087 citations recorded by the source corpus.

Subfields: Biomaterials, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/4e763d0fe931b56cbefe0a54566fe203701789c9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Molecular Biology

Citations in the corpus

Small particles, big impacts: A review of the diverse applications of nanofluids (2013, methodology): “Nanofluids in Medical Applications In the medical field, nanofluids have been used extensively [94], [282–284].”
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. (2013, positive): “Likely, there are several reasons for this 2,9,11,12 , but certainly there remains a lack of detailed mechanistic information on the link between nanoparticle surface and biological interactions.”
Gold nanoparticles: Optical properties and implementations in cancer diagnosis and photothermal therapy (2010, background): “These new properties, including optical, magnetic, electronic, and structural properties, make nano-sized particles (generally 1–100 nm) very promising for a wide range of biomedical applications such as cellular imaging, molecular diagnosis and targeted therapy depending on the structure, composite”
Biomedical Nanomagnetics: A Spin Through Possibilities in Imaging, Diagnostics, and Therapy (2010, positive): “One important example of the potential benefits of combining magnetic properties and tailored surface properties relates to a common problem in cancer therapy, namely that most current anti-cancer agents do not differentiate between cancerous and normal cells [143].”
Nanoparticles for Biomedical Imaging: Fundamentals of Clinical Translation (2010, background): “Like any contrast agent used for biomedical imaging, NPs must be designed to have a reasonable blood half-life, minimal nonspecific binding and uptake, selective binding to desired epitopes, such as cell surface receptors, effective elimination from the body (when NP components have any potential fo”